Terms: = Leukemia AND REL, I-Rel, 5966, ENSG00000162924, C-Rel AND Treatment
52 results:
1. Conferone, a coumarin from
Rafatpanah H; Golizadeh M; Mahdifar M; Mahdavi S; Iranshahi M; Rassouli FB
Int J Immunopathol Pharmacol; 2023; 37():3946320231197592. PubMed ID: 37688389
[TBL] [Abstract] [Full Text] [Related]
2. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract] [Full Text] [Related]
3. Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Sharman JP; Miranda P; Roos J; Emeribe U; Cai L; Liljas B; Gaitonde P
Leuk Lymphoma; 2023; 64(7):1243-1252. PubMed ID: 37221877
[TBL] [Abstract] [Full Text] [Related]
4. Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results.
Avenarius MR; Huang Y; Hyak J; Byrd JC; Bhat SA; Grever M; Kittai AS; Rogers KA; Jones D; Zhao W; Heerema NA; Abruzzo LV; Woyach J; Miller CR
Hematol Oncol; 2023 Oct; 41(4):771-775. PubMed ID: 37010242
[TBL] [Abstract] [Full Text] [Related]
5. A novel approach for relapsed/refractory FLT3
Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
[TBL] [Abstract] [Full Text] [Related]
6. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
[TBL] [Abstract] [Full Text] [Related]
7. Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (rel).
Borlenghi E; Pagani C; Zappasodi P; Bernardi M; Basilico C; Cairoli R; Fracchiolla N; Todisco E; Turrini M; Cattaneo C; Da Vià M; Ciceri F; Passamonti F; Mancini V; Sciumè M; Cerqui E; Sciumè M; Rossi G
J Geriatr Oncol; 2021 May; 12(4):550-556. PubMed ID: 33097455
[TBL] [Abstract] [Full Text] [Related]
8. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT).
Poiani M; Labopin M; Battipaglia G; Beelen DW; Tischer J; Finke J; Brecht A; Forcade E; Ganser A; Passweg JR; Labussiere-Wallet H; Yakoub-Agha I; Schäfer-Eckart K; Kroeger N; Guffroy B; Ruggeri A; Esteve J; Nagler A; Mohty M
Am J Hematol; 2021 Jan; 96(1):40-50. PubMed ID: 32944990
[TBL] [Abstract] [Full Text] [Related]
9. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
Solem CT; Bell TJ; Kwon Y; Cappelleri JC; Johnson C; Bhattacharyya H; Hoang CJ; Cortes JE
Cancer; 2020 Oct; 126(19):4315-4321. PubMed ID: 32697335
[TBL] [Abstract] [Full Text] [Related]
10. Reversal of Epigenetic Silencing Allows Robust HIV-1 Replication in the Absence of Integrase Function.
Irwan ID; Karnowski HL; Bogerd HP; Tsai K; Cullen BR
mBio; 2020 Jun; 11(3):. PubMed ID: 32487757
[TBL] [Abstract] [Full Text] [Related]
11. BIRC3 Expression Predicts CLL Progression and Defines treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
[TBL] [Abstract] [Full Text] [Related]
12. Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
Zappasodi P; Marbello L; Borlenghi E; Fumagalli M; Bernardi M; Fracchiolla N; Mancini V; Da Vià M; Ravano E; Cerqui E; Ferretti VV; Rocca B; Calvello C; Cazzola M; Castagnola C; Rossi G
Ann Hematol; 2018 Nov; 97(11):2107-2115. PubMed ID: 30009341
[TBL] [Abstract] [Full Text] [Related]
13. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.
Herrera AF; Rodig SJ; Song JY; Kim Y; Griffin GK; Yang D; Nikolaenko L; Mei M; Bedell V; Dal Cin P; Pak C; Alyea EP; Budde LE; Chen R; Chen YB; Chan WC; Cutler CS; Ho VT; Koreth J; Krishnan A; Murata-Collins JL; Nikiforow S; Palmer J; Pihan GA; Pillai R; Popplewell L; Rosen ST; Siddiqi T; Sohani AR; Zain J; Kwak LW; Weisenburger DD; Weinstock DM; Soiffer RJ; Antin JH; Forman SJ; Nademanee AP; Armand P
Biol Blood Marrow Transplant; 2018 Mar; 24(3):514-520. PubMed ID: 29196080
[TBL] [Abstract] [Full Text] [Related]
14. HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
Jia YJ; Liu ZB; Wang WG; Sun CB; Wei P; Yang YL; You MJ; Yu BH; Li XQ; Zhou XY
Leukemia; 2018 Mar; 32(3):703-711. PubMed ID: 29135973
[TBL] [Abstract] [Full Text] [Related]
15. Inhibition of c-rel using siRNA increased apoptosis and decreased proliferation in pre-B ALL blasts: Therapeutic implications.
Mohammadi SM; Mohammadnejad D; Hosseinpour Feizi AA; Movassaghpour AA; Montazersaheb S; Nozad Charoudeh H
Leuk Res; 2017 Oct; 61():53-61. PubMed ID: 28892661
[TBL] [Abstract] [Full Text] [Related]
16. [Role of Non-classical NF-κB Signaling Pathway in B Acute Lymphoblastic leukemia].
Liu XL; Cai Y; Li BJ; Huang WB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1639-1643. PubMed ID: 28024469
[TBL] [Abstract] [Full Text] [Related]
17. The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
Molteni A; Riva M; Borin L; Bernardi M; Pelizzari AM; Freyrie A; Della Porta M; Nichelatti M; Ravano E; Quaresmini G; Mariotti J; Caramazza D; Ubezio M; Guarco S; Gigli F; Greco R; Cairoli R; Morra E
Leuk Res; 2016 Mar; 42():21-7. PubMed ID: 26852003
[TBL] [Abstract] [Full Text] [Related]
18. NFkB is activated by multiple mechanisms in hairy cell leukemia.
Nagel S; Ehrentraut S; Meyer C; Kaufmann M; Drexler HG; MacLeod RA
Genes Chromosomes Cancer; 2015 Jul; 54(7):418-32. PubMed ID: 25960206
[TBL] [Abstract] [Full Text] [Related]
19. Mapping the Interaction of B Cell leukemia 3 (BCL-3) and Nuclear Factor κB (NF-κB) p50 Identifies a BCL-3-mimetic Anti-inflammatory Peptide.
Collins PE; Grassia G; Colleran A; Kiely PA; Ialenti A; Maffia P; Carmody RJ
J Biol Chem; 2015 Jun; 290(25):15687-15696. PubMed ID: 25922067
[TBL] [Abstract] [Full Text] [Related]
20. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract] [Full Text] [Related]
[Next]
